New Approaches for the Treatment of Chagas Disease
- PMID: 33238855
- DOI: 10.2174/1389450121999201124122643
New Approaches for the Treatment of Chagas Disease
Abstract
Chagas disease, caused by the protozoan Trypanosoma cruzi is a neglected tropical disease with high prevalence (5.7 million in Latin America, WHO 2015), significant burden, and significant morbimortality mostly due to severe heart disorders during the chronic phase of infection. Chagas disease is endemic in Latin America, and medical care for the disease is the major expense for Brazil's Universal Healthcare System (Sistema Único de Saúde (SUS). The efficacy of the available drugs benznidazole and nifurtimox are low for the chronic phase of Chagas disease, the phase in which most patients are diagnosed, and there are frequent side effects, and drug resistance occurs. The rapid deployment of new drug regimens that are effective for the chronic phase treatment is low-cost and less toxic than the currently available therapy, which is a global priority. Repurposing drugs already in clinical use with other combinations would be the fastest and safest strategy for treating Chagas disease patients. We hypothesize that the combined treatment using repurposing drugs with benznidazole will be more efficacious than benznidazole alone. This needs to be tested further both in vitro and in animal models to understand the efficacy of the treatment before performing human clinical trials. We further hypothesize that producing nanoparticle formulation of the drugs can reduce their toxicity and improve therapeutic use.
Keywords: Chagas disease; Heart disorders; Nanoparticle formulation; Repurposing drugs; Trypanosoma cruzi; benznidazole.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).Cochrane Database Syst Rev. 2020 Dec 11;12(12):CD004102. doi: 10.1002/14651858.CD004102.pub3. Cochrane Database Syst Rev. 2020. PMID: 33305846 Free PMC article.
-
Current drug therapy and pharmaceutical challenges for Chagas disease.Acta Trop. 2016 Apr;156:1-16. doi: 10.1016/j.actatropica.2015.12.017. Epub 2015 Dec 30. Acta Trop. 2016. PMID: 26747009 Review.
-
Drug discovery for chagas disease: A viewpoint.Acta Trop. 2019 Oct;198:105107. doi: 10.1016/j.actatropica.2019.105107. Epub 2019 Jul 24. Acta Trop. 2019. PMID: 31351074 Review.
-
Current status of Chagas disease chemotherapy.Expert Rev Anti Infect Ther. 2011 May;9(5):609-20. doi: 10.1586/eri.11.31. Expert Rev Anti Infect Ther. 2011. PMID: 21609270 Review.
-
Experimental and Clinical Treatment of Chagas Disease: A Review.Am J Trop Med Hyg. 2017 Nov;97(5):1289-1303. doi: 10.4269/ajtmh.16-0761. Epub 2017 Oct 10. Am J Trop Med Hyg. 2017. PMID: 29016289 Free PMC article. Review.
Cited by
-
Chagas Disease: Comparison of Therapy with Nifurtimox and Benznidazole in Indigenous Communities in Colombia.J Clin Med. 2024 Apr 26;13(9):2565. doi: 10.3390/jcm13092565. J Clin Med. 2024. PMID: 38731093 Free PMC article.
-
Piplartine-Inspired 3,4,5-Trimethoxycinnamates: Trypanocidal, Mechanism of Action, and In Silico Evaluation.Molecules. 2023 Jun 2;28(11):4512. doi: 10.3390/molecules28114512. Molecules. 2023. PMID: 37298988 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical